Your Feed

Filter by
See content from
Back to the latest
Avatar
silverLadybug
Multiple Myeloma Discussion • January 7, 2025
Light Chain Test Accuracy and Variability?
AI-generated title
Dear Myeloma Community, Great day, I am 70 years old, diagnosed with Myeloma since almost two years. I am now on Lenalidomide 10mg maintenance dose. I am monitoring the Kappa Light Chains, being my type of disease, as an important marker for progression. I have no m-spike. The outcomes are different from Lab to Lab. Such as I got 129 from one lab and 89 from the other with 1 day difference between giving the blood samples. My question: did anybody come across the question of the accuracy/ tolerance of this test? Is it plus or minus 5%, 10% or? I am not able to judge or find an answer. My doctor says I don't need further tests like a Biopsy or PET, but we need to monitor my condition monthly. Please let me know if you have a similar situation or can help somehow with an advice. Rgds to all
Thumbnail for Allogeneic & Autologous Stem Cell Transplant for Follicular Lymphoma | Yasmina Serroukh, MD | #ASH24
Playlist: ASH 2024

Allogeneic & Autologous Stem Cell Transplant for Follicular Lymphoma | Yasmina Serroukh, MD | #ASH24

Video details & playlist
Thumbnail for Odronextamab as First-Line Therapy in Follicular Lymphoma | Rueme Birhiray, MD | #ASH24
Playlist: ASH 2024

Odronextamab as First-Line Therapy in Follicular Lymphoma | Rueme Birhiray, MD | #ASH24

Video details & playlist
Thumbnail for Phase 3 Asciminib Tolerability Trial , ASC4FIRST, for Patients with CML | David Andorsky |#ASH2024
Playlist: ASH 2024

Phase 3 Asciminib Tolerability Trial , ASC4FIRST, for Patients with CML | David Andorsky |#ASH2024

Video details & playlist
Thumbnail for The Phase 2 ASC2ESCALATE Trial Evaluating Asciminib for CML Patients | David Andorsky, MD | #ASH2024
Playlist: ASH 2024

The Phase 2 ASC2ESCALATE Trial Evaluating Asciminib for CML Patients | David Andorsky, MD | #ASH2024

Video details & playlist
Thumbnail for Race, Ethnicity, and Socioeconomics Tied to Disparities in Myelofibrosis | Anand Patel, MD | #ASH24
Playlist: ASH 2024

Race, Ethnicity, and Socioeconomics Tied to Disparities in Myelofibrosis | Anand Patel, MD | #ASH24

Video details & playlist
Thumbnail for Fedratinib Helps Myelofibrosis Patients with Low Platelet Counts | Haifa Katrhin Al-Ali, MD | #ASH24
Playlist: ASH 2024

Fedratinib Helps Myelofibrosis Patients with Low Platelet Counts | Haifa Katrhin Al-Ali, MD | #ASH24

Video details & playlist
Thumbnail for BTK Degrader Study Shows Promise for a New Class of CLL Therapies | Alexey Danilov MD PhD | #ASH2024
Playlist: ASH 2024

BTK Degrader Study Shows Promise for a New Class of CLL Therapies | Alexey Danilov MD PhD | #ASH2024

Video details & playlist
Thumbnail for Duration of BTKi therapy correlates with time to next treatment in CLL | Kerry Rogers, MD | #ASH24
Playlist: ASH 2024

Duration of BTKi therapy correlates with time to next treatment in CLL | Kerry Rogers, MD | #ASH24

Video details & playlist
Thumbnail for Importance of Support for Caregivers of Transfusion Dependent Patients | Maria Diez-Campelo | #ASH24
Playlist: ASH 2024

Importance of Support for Caregivers of Transfusion Dependent Patients | Maria Diez-Campelo | #ASH24

Video details & playlist